Jul 08 2023 64 mins 1
Charles Fisher is the Founder and CEO of Unlearn, that creates digital twins with AI to enable more efficient clinical trials. Founded in 2017, Unlearn started as a generative AI company looking for a problem, ending up on clinical trials & transforming how they are run. A digital Twin is a longitudinal/clinical record using baseline data from a patient before they receive their 1st treatment. To predict how the patient would likely progress in the trial if given a placebo. And increase statistical power of the trial without enrolling more patients. Unlearn sells their TwinRCT product to companies & institutions to optimize their clinical trials. Signing a multi-year collaboration with German Merck in 2022 and getting EMA qualification for phase 2/3 trials later that year. Initially focused on AD & MS. Unlearn is improving trial efficiency, with 12%-39% fewer subjects required, and helping lower the costs it takes to develop new medicines for neurodegeneration, inflammatory disease, and more.
Charles discusses his career starting as a scientist with interests at the intersection of physics, machine learning, and computational biology. Then joining Leap Motion as a machine learning engineering and Pfizer as a computational biologist. All leading up to starting Unlearn.
